Trevena (NASDAQ:TRVN) Shares Cross Below Two Hundred Day Moving Average – Should You Sell?

Trevena, Inc. (NASDAQ:TRVN) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.53 and traded as low as $0.99. Trevena shares last traded at $1.09, with a volume of 2,806 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Trevena in a report on Thursday. They set a “sell” rating on the stock.

Trevena Trading Down 9.2%

The stock has a market capitalization of $941,760.00, a price-to-earnings ratio of -0.02 and a beta of 0.87. The firm has a 50-day moving average of $1.23 and a 200-day moving average of $1.53.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.